Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

15 Jan 2021

• By Ian Haydock, Joseph Haas, and Jung Won Shin

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

More from Deals

More from Business